On in vi­vo cell ther­a­py quest, Take­da-backed En­so­ma buys a CRISPR up­start and bags $85M

Cell ther­a­py biotech En­so­ma made an all-stock ac­qui­si­tion of Dan­ish CRISPR tech­nol­o­gy up­start Twelve Bio, and al­so raised an $85 mil­lion Se­ries B.

The Boston biotech will use the pro­ceeds to bring its lead on­col­o­gy pro­gram in­to the clin­ic, with the goal of tar­get­ing hematopoi­et­ic stem cells with a one-time, off-the-shelf ther­a­py, CEO Emile Nuwaysir told End­points News. Nuwaysir joined the Take­da-al­lied biotech in the fall of 2021, af­ter lead­ing Parkin­son’s-fo­cused Blue­Rock to an ex­it to Bay­er. En­so­ma had re­mained rel­a­tive­ly qui­et from his ar­rival un­til the fi­nanc­ing and M&A dis­clo­sure on Thurs­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN